Data presented at the European Academy of Neurology Congress 2023: Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine JULY 2023, TEL AVIV, Israel: Teva Pharmaceutical Industries Ltd has announced further positive data from…
AI in stroke: tool outperforms human emergency call handlers in identifying stroke
AI in stroke: A team of researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.[i] The framework outperformed emergency call handlers in recognising stroke for both sexes and across all age groups studied, indicating its potential as a supplementary…
Could new materials lead to implantable treatments for epilepsy?
Breakthrough research on materials may help new types of probes be safely implanted in the brain. Bioengineering researchers from the University of Glasgow have investigated new dissolvable coatings which could help safely guide flexible implants into brains to help regulate temporal lobe epilepsy. The development of the material, outlined in an early-view paper in the…
Opicapone 50mg in adult levodopa treated PD patients without motor complications
BIAL announces positive results from phase 3 study June 5th, 2023: BIAL announces positive topline results of its phase 3 EPSILON (Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe) study evaluating opicapone 50mg in adult levodopa treated Parkinson’s Disease (PD) patients without motor complications. In the EPSILON study, opicapone 50 mg was found to be statistically significantly…
Janssen is a proud sponsor of the ABN-INA joint meeting
Janssen is proud to have sponsored the recent ABN-INA joint meeting in Belfast. We recognise the educational impact of events like these, and are grateful to the delegates who attended our lunchtime symposium on Wednesday 10th on the topic of ‘How can brain volume measures inform clinical practice? What have we learned from multiple sclerosis?’…
Seer partners with NHS hospitals
Seer partners with NHS hospitals to deliver cloud-based video-EEG-ECG monitoring services that enhance the efficiency of neurology and neurophysiology teams. Seer supports the integration of home-based diagnostics into current clinical workflows through the Seer Home service, a range of home video telemetry offerings. Hospitals can access customised services — including patient set-up, home-based monitoring, data…
Grant to explore new epilepsy treatment for Tuberous Sclerosis Complex (TSC)
Dr Felix Chan awarded £174k grant to study Tuberous Sclerosis Complex (TSC) and epilepsy by Epilepsy Research UK. The new study will investigate lysine metabolism as a therapeutic target for epilepsy in TSC Research designed with TSC and epilepsy patient community through Tuberous Sclerosis Association and Epilepsy Research UK. A researcher based in Aston Institute for…
New government concussion guidance
New guidelines for recognising and managing concussion in grassroots sports have been published by the Government. Aimed at the general public and those engaging with sport on a non-professional level, ‘If In Doubt, Sit Them Out’ is guidance with a very clear message that if an individual is suspected of having concussion, they must be…
Eisai submits a marketing authorisation application (MAA) for lecanemab
Eisai has submitted a Marketing Authorisation Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in the brain,1 to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. This…